Marvin J. Miller

Professor, Department of Chemistry and Biochemistry
University of Notre Dame, Notre Dame, IN 46556
(219) 631-7571 (email: Marvin.J.Miller.2@nd.edu)

Biographical Notes

Professor Miller received his B.S. in chemistry from North Dakota State University in 1971 and his Ph.D. from Cornell University in 1976, where he developed a method for carboxyterminal peptide degradation. During subsequent postdoctoral studies as an NIH Fellow in the Department of Chemistry at the University of California, Berkeley (1975- 1977), he studied the nature of porphyrin-peptide linkage in cytochromes and became involved in pyrrole syntheses. Since joining the chemistry faculty at Notre Dame in 1977, his emphasis has been in synthetic and bioorganic chemistry. He was an Alfred P. Sloan Fellow from 1981-85, an NIH Research Career Development Awardee (1983-1988), a visiting Fellow at the Australian National University (1988), a consultant for Eli Lilly and Co. (1980-), and is a member of the Editorial Advisory Board of Journal of Organic Chemistry. He has been an invited plenary lecturer at a number of international meetings and symposia and a frequent invited contributor to symposia-in-print. Dr. Miller received the 1994 Shilts/Leonard Teaching Award of the College of Science at the University of Notre Dame for excellence in teaching.

Research Summary: Synthetic Organic and Bioorganic Chemistry

Dr. Miller's research program is internationally recognized as a leader in the design, synthesis and study of new antibiotics, especially beta- lactams, siderophores (microbial iron chelators) and conjugates. His research is centered on the development of new methodology and its incorporation into the synthesis and study of biologically important compounds. Special emphasis is given to asymmetric syntheses and studies of hydroxamic acid containing microbial iron transport agents (siderophores), amino acids, peptides, §-lactam antibiotics, novel antifungal agents, potential antimalarial agents, carbocyclic analogs of antifungal and anticancer nucleosides and MRI (Magnetic Resonance Imaging) contrast agents.

Click here for recent publications

This page has been visited times since September 25, 1995.